Infinity Pharmaceuticals (INFI) said preliminary results from its IPI-549 drug trial showed that the cancer treatment can reverse tumor resistance to checkpoint inhibitors.
- PR Newswire•2 days agoInfinity Presents Initial Clinical And New Preclinical Data On IPI-549 At Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
CAMBRIDGE, Mass., Sept. 26, 2016 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced initial clinical and new preclinical data for IPI-549, an orally administered immuno-oncology ...
- PR Newswire•10 days ago
CAMBRIDGE, Mass., Sept. 19, 2016 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the publication of new findings by research collaborators at University of California San ...
Infinity Pharmaceuticals, Inc. (INFI)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||1.51 x 500|
|Ask||1.75 x 2500|
|Day's Range||1.54 - 1.60|
|52wk Range||1.24 - 10.85|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||5.08|
|Avg Vol (3m)||785,362|
|Dividend & Yield||N/A (N/A)|